The global prostate health market size is expected to reach USD 68.0 billion by 2030, according to a new study by Polaris Market Research. The report “Prostate Health Market Share, Size, Trends, Industry Analysis Report, By Disease Indication (Prostate Cancer, Benign Prostate Hyperplasia (BPH), Prostatitis); By Modality (Diagnosis, Treatment); By Treatment (Surgery, Radiation Therapy, Therapeutics); By Region; Segment Forecast, 2022 – 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The market’s growth is driven by increasing investments and grants from government organizations in cancer. Various groups are raising cancer awareness and encouraging innovative cancer treatments. This is enhanced by offering funds to researchers to further their research.
The various cancer organizations actively supporting cancer through grants include Prostate Cancer Foundation, Cancer Research Institute, Zero organizations, the American Cancer Society, etc. There is an extensive network of cancer organizations in North America and Europe. The Cancer Research Institute has granted 100 research grants to studies and initiatives related to cancer. The organization is investing heavily in new immunotherapy health treatments for cancer. The financial support totals around $26 Billion, with $9 Billion of the CRI Prostate Cancer Initiative funds.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/prostate-health-market/request-for-sample
Based on the treatment, the radiation therapy segment accounted for the leading share in the market in 2021. Radiation therapy kills cancer cells by utilizing high-powered light. External beam radiation therapy is a treatment option for cancer. It can also be administered after surgery to eliminate any remaining cancer cells if there is a chance that the tumor will spread or return.
Radiation treatment can help slow down the growth of cancer and ease pain such as discomfort if it has migrated to other parts of the body, such as the bones. Thus, the benefits of radiation therapy for cancer are boosting segmental growth.
Market players include Abbott Laboratories, Amgen Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Merck & Co., Inc., Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Ferring Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Johnson & Johnson, and Siemens Healthcare AG.are some key players operating in the global market.
Polaris Market Research has segmented the prostate health market report based on disease indication, modality, treatment, and region:
Prostate Health, Disease Indication Outlook (Revenue – USD Billion, 2018 – 2030)
- Prostate Cancer
- AR Directed Therapies
- Hormone ADT
- Cytotoxic Agents
- PARP Inhibitors
- Benign Prostate Hyperplasia (BPH)
- Other Alpha Blockers
- 5 Alpha Reductase
- Over the counter
Prostate Health, Modality Outlook (Revenue – USD Billion, 2018 – 2030)
Prostate Health, Treatment Outlook (Revenue – USD Billion, 2018 – 2030)
- Radiation Therapy
- Hormone Therapy
Prostate Health, Regional Outlook (Revenue – USD Billion, 2018 – 2030)
- North America
- Asia Pacific
- South Korea
- Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa